Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)
South Korea flag South Korea · Delayed Price · Currency is KRW
9,520.00
+370.00 (4.04%)
May 13, 2025, 3:30 PM KST
-40.50%
Market Cap 221.41B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 23.26M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 541,716
Average Volume 888,910
Open 10,130.00
Previous Close 9,150.00
Day's Range 9,380.00 - 10,300.00
52-Week Range 6,970.00 - 25,200.00
Beta 3.39
RSI 53.24
Earnings Date n/a

About Vaxcell-Bio Therapeutics

Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 323990
Full Company Profile

Financial Performance

In 2024, Vaxcell-Bio Therapeutics's revenue was 1.90 billion, an increase of 13737.28% compared to the previous year's 13.72 million. Losses were -10.62 billion, 3.40% more than in 2023.

Financial Statements

News

There is no news available yet.